Drug Profile
CSTC 1
Alternative Names: CSTC1Latest Information Update: 23 Feb 2022
Price :
$50
*
At a glance
- Originator Charsire Biotechnology Corporation
- Class Antidementias; Foot disorder therapies; Phytotherapies; Skin disorder therapies; Vascular disorder therapies
- Mechanism of Action Interleukin 1 beta inhibitors; Platelet derived growth factor stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Diabetic foot ulcer
Most Recent Events
- 15 Feb 2022 Phase-II clinical trials in Diabetic foot ulcer in USA (Topical) before February 2022 (Charsire Biotechnology Corporation's pipeline , February 2022)
- 15 Feb 2022 Phase-II development in Diabetic foot ulcers is still ongoing in Taiwan (Topical) (Charsire Biotechnology Corporation's pipeline, February 2022)
- 15 Feb 2022 Charsire Biotechnology Corporation plans a phase III trial for Diabetic foot ulcer (Topical) (Charsire Biotechnology Corporation's pipeline, February 2022)